Media stories about AMAG Pharmaceuticals (NASDAQ:AMAG) have trended somewhat positive this week, Accern Sentiment Analysis reports. Accern rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 45.3227192933392 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media stories that may have effected Accern Sentiment’s scoring:

AMAG Pharmaceuticals (NASDAQ AMAG) traded up 2.93% during midday trading on Monday, reaching $15.80. 837,266 shares of the company’s stock traded hands. The company’s market capitalization is $557.55 million. AMAG Pharmaceuticals has a 1-year low of $14.90 and a 1-year high of $36.83. The firm’s 50 day moving average price is $18.05 and its 200-day moving average price is $18.80.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.18. The company had revenue of $158.39 million for the quarter, compared to analyst estimates of $158.83 million. AMAG Pharmaceuticals had a negative net margin of 7.58% and a negative return on equity of 4.81%. AMAG Pharmaceuticals’s quarterly revenue was up 24.3% on a year-over-year basis. During the same period in the previous year, the business posted $1.45 earnings per share. Equities analysts expect that AMAG Pharmaceuticals will post ($1.39) EPS for the current year.

AMAG has been the topic of a number of recent analyst reports. Zacks Investment Research raised AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Tuesday, July 11th. Janney Montgomery Scott reissued a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Monday, October 23rd. ValuEngine raised AMAG Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Tuesday, July 25th. Morgan Stanley started coverage on AMAG Pharmaceuticals in a research report on Friday, September 8th. They issued an “overweight” rating and a $26.00 target price on the stock. Finally, Deutsche Bank AG reissued a “hold” rating and issued a $24.00 target price on shares of AMAG Pharmaceuticals in a research report on Thursday, August 31st. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $25.83.

TRADEMARK VIOLATION WARNING: This piece was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://theolympiareport.com/2017/10/30/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-amag-pharmaceuticals-amag-share-price.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Insider Buying and Selling by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.